CN1127115A - 3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷化合物在抗肿瘤治疗中的应用 - Google Patents

3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷化合物在抗肿瘤治疗中的应用 Download PDF

Info

Publication number
CN1127115A
CN1127115A CN95116888A CN95116888A CN1127115A CN 1127115 A CN1127115 A CN 1127115A CN 95116888 A CN95116888 A CN 95116888A CN 95116888 A CN95116888 A CN 95116888A CN 1127115 A CN1127115 A CN 1127115A
Authority
CN
China
Prior art keywords
hydrogen
octane
thia
diazabicyclo
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95116888A
Other languages
English (en)
Inventor
M·科瓦塞维克
M·格迪萨
K·帕维里克
M·霍瓦蒂克
Z·曼迪克
M·托米克
J·J·赫拉克
I·卢基克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd filed Critical Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Publication of CN1127115A publication Critical patent/CN1127115A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及具有通式I的3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷(其中的基团具有下列含义:R1为氢、卤素,R2为氢、卤素、氨基、PhCH2CONH、PhOCH2CONH、苯二甲酰亚氨基、邻-甲基NHCOC6H4CONH、3-邻-氯苯基-5-甲基-异噁唑基-4-羰基氨基,R3为氢、烷基、苄基、杂环如异噁唑、吡唑,n是1或2)。在应用实施例中公开了用各种取代的3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷衍生物抑制子宫颈癌细胞(Hela)的作用。

Description

3,8-二氧代-5-硫代-1,4-二氮杂二环 〔4.2.0〕辛烷化合物在抗肿瘤治疗中的应用
我们在1994年5月25日的在先申请EP 0598375 A2中描述了具有通式I的3,8-二氧代-5-硫代-1,4-二氮杂二环〔4.2.0〕辛烷化合物
Figure A9511688800031
其中的基团具有下列含义:
R1  为氢、卤素,
R2  为氢、卤素、氨基、PhCH2CONH、PhOCH2CONH、
     苯二甲酰亚氨基、邻-甲基NHCOC6H4CONH、
     3-邻-氯苯基-5-甲基-异噁唑基-4-羰基氨基,
R3  为氢、烷基、苄基、杂环如异噁唑、吡唑,
n是1或2,及其在抗菌治疗中作为药物有效成分的有效性。
本发明也涉及具有通式I的化合物,以及,特别是,其以规定量加入能有效抑制肿瘤细胞的药物制剂中作为有效成分的用途。
根据我们对现有技术的了解,还未知在抗肿瘤治疗中使用过具有类似结构或任何其它β-内酰胺结构的化合物。
我们发现具有通式I的3,8-二氧代-5-硫代-1,4-二氮杂二环〔4.2.0〕辛烷类似物(其中的基团具有上述含义)可以很强地抑制子宫颈癌细胞(HeLa)的生长。通过使用浓度为10-3-10-6M的式I化合物,72小时后对肿瘤细胞的抑制效果达到25%-65%。在浓度为5×10-4M时获得了最好的效果。
下列实施例是关于具有通式I的化合物对子宫颈癌的抑制效果,表明了该化合物还能有效地抑制其它肿瘤细胞的可能性。检测方法
将细胞于DMEM(Dulbecco改进的Eagle培养基)生长培养基中〔其中补充了胎牛血清(FCS)(10%)、谷氨酰胺(2mM)、青霉素(100U/ml)、链霉素(100μg/ml)和Hepes(1mM)〕在pH7、温度为37℃以及在含有空气和5%CO2的混合气流通的条件下培养12小时之内。将104细胞/ml浓度的细胞于24或96孔细胞培养平板上增殖。12小时后,加入浓度为10-3-10-6M的式I化合物溶液。先将所有物质在二甲基甲酰胺中制备成10-M的溶液,再用细胞生长培养基稀释成所需浓度。加入活性物质72小时后用电子计数器进行细胞计数,测定化合物I的抑制效果,如下列实施例中所示:
               化合物                        浓度               抑制率实施例1
Figure A9511688800051
                                           1×10-4M              65%实施例2
Figure A9511688800052
                                           1×10-4M              50%实施例3
Figure A9511688800053
                                           1×10-4M              40%实施例4
Figure A9511688800054
                                           1×10-4M              40%实施例5
Figure A9511688800061
                                      1×10-4M                25%

Claims (1)

1.具有通式I的3,8-二氧代-5-硫代-1,4-二氮杂二环〔4.2.0〕辛烷化合物
Figure A9511688800021
其中的基团具有下列含义:
R1为氢、卤素,
R2为氢、卤素、氨基、PhCH2CONH、PhOCH2CONH、苯二甲酰亚氨基、邻-甲基NHCOC6H4CONH、3-邻-氯苯基-5-甲基-异噁唑基-4-羰基氨基,
R3为氢、烷基、苄基、杂环如异噁唑、吡唑,
n是1或2,
以规定量加入对肿瘤治疗有效的药物制剂中作为有效成分的用途。
CN95116888A 1994-09-21 1995-09-21 3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷化合物在抗肿瘤治疗中的应用 Pending CN1127115A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP940577A 1994-09-21
HR940577A HRP940577B1 (en) 1994-09-21 1994-09-21 Use of 5-thia-1,4-diazabicyclo (4.2.0) octane-3,8-dioxo compounds in antitumor therapy

Publications (1)

Publication Number Publication Date
CN1127115A true CN1127115A (zh) 1996-07-24

Family

ID=10946157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95116888A Pending CN1127115A (zh) 1994-09-21 1995-09-21 3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷化合物在抗肿瘤治疗中的应用

Country Status (14)

Country Link
EP (1) EP0705606B1 (zh)
JP (1) JPH08310954A (zh)
CN (1) CN1127115A (zh)
AT (1) ATE164069T1 (zh)
BG (1) BG62237B1 (zh)
CA (1) CA2158678C (zh)
CZ (1) CZ285621B6 (zh)
DE (1) DE69501810T2 (zh)
ES (1) ES2115303T3 (zh)
HR (1) HRP940577B1 (zh)
HU (1) HU218287B (zh)
RU (1) RU2136284C1 (zh)
SI (1) SI9500297A (zh)
SK (1) SK280815B6 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035518A1 (zh) * 2009-09-23 2011-03-31 辽宁利锋科技开发有限公司 嘧啶衍生物和类似物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598188A (en) * 1979-01-23 1980-07-25 Mitsui Toatsu Chem Inc Novel cephalosporin and its preparation
JPS57171994A (en) * 1981-04-15 1982-10-22 Asahi Chem Ind Co Ltd Novel compound
HRP921292A2 (en) 1992-11-17 1994-08-31 Pliva Pharm & Chem Works 5-thia-1,4-diazabicyclo (4.2.0.)octane -3,8-dioxo analogs of beta-lactams, the process for the preparation and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035518A1 (zh) * 2009-09-23 2011-03-31 辽宁利锋科技开发有限公司 嘧啶衍生物和类似物及其制备方法和用途

Also Published As

Publication number Publication date
SK117095A3 (en) 1996-09-04
EP0705606B1 (en) 1998-03-18
SK280815B6 (sk) 2000-08-14
CA2158678A1 (en) 1996-03-22
CZ285621B6 (cs) 1999-10-13
CZ244795A3 (en) 1996-04-17
HU9502770D0 (en) 1995-11-28
DE69501810T2 (de) 1998-09-24
ATE164069T1 (de) 1998-04-15
BG100020A (bg) 1996-04-30
BG62237B1 (bg) 1999-06-30
ES2115303T3 (es) 1998-06-16
HRP940577A2 (en) 1997-04-30
HUT74422A (en) 1996-12-30
RU2136284C1 (ru) 1999-09-10
HU218287B (en) 2000-07-28
DE69501810D1 (de) 1998-04-23
EP0705606A1 (en) 1996-04-10
SI9500297A (en) 1996-04-30
CA2158678C (en) 2000-04-18
HRP940577B1 (en) 1998-12-31
JPH08310954A (ja) 1996-11-26

Similar Documents

Publication Publication Date Title
JP2604783B2 (ja) ビスーナフタルイミド及びこれを含有する腫瘍抑制及び抗白血病作用を有する医薬
CA1226220A (en) Preparation and method for the treatment of acne
NO20021401L (no) Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser
EE05530B1 (et) Gamma-aminov?ihappe derivaate sisaldavad tahked kompositsioonid ja nende saamise meetod
IL205420A (en) Immunogoldular and Derivative Compounds, Pharmaceutical Compounds in the Treatment of Inflammatory Stomach and Gastrointestinal Disorders
US6329497B1 (en) Sandramycin analogs
ATE201671T1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
US4634707A (en) 5-Pyrimidinecarboxamides and treatment of leukemia and tumors therewith
CA2486872A1 (en) Nf-kb inhibitors and uses thereof
KR860001389B1 (ko) 나트로안식향산 아미드 유도체의 제조방법
CN1127115A (zh) 3,8-二氧代-5-硫代-1,4-二氮杂二环[4.2.0]辛烷化合物在抗肿瘤治疗中的应用
CA1336506C (en) Method for protection from chemotherapeutic side effects
US6037357A (en) N-benzoyl-α-alkylated azatyrosines as anticancer agents
IL70253A (en) N-nitrosourea phosphoric acid derivatives,their preparation and pharmaceutical compositions containing them
US5391558A (en) Composition for accelerating healing of wound
RU2150274C1 (ru) Стабилизированная водорастворимая композиция трийодида 1,2,3-триалкилбензимидазолия
HUP0204572A2 (en) Substituierte bisindolylmaleinimide derivatives, process for their preparation and use and pharmaceutcial compositions containing them
US4377583A (en) N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid
US4920126A (en) Barbituric acid derivative and treatment of leukemia and tumors therewith
EP0537177B1 (en) Nitrogen and silver containing derivative
JPH1095733A (ja) にきび治療薬
SU803351A1 (ru) Ацетиламиноалкил- @ -диазокетоны,обладающие противоопухолевой активностью
JPS61176559A (ja) 2‐アダマンタノンオキシムカルバメート誘導体
MXPA00012261A (en) N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
MX9503130A (es) Inhibidores de metaloproteinasa, proceso para su preparacion y composiciones farmaceuticas o veterinarias que los contienen.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication